News
3 September, 2026
Disruptive Pharma to participate in SweDeliver Summit 2026
Evelina Meurling and Ellen Brunzell will represent Disruptive Pharma at the SweDeliver Summit 2026, an annual meeting bringing together academia and industry in drug delivery and pharmaceutical development. The SweDeliver network provides an important forum for exchanging experience, sharing perspectives and staying closely connected to developments...
31 August, 2026
Disruptive Pharma to attend Nordic Life Science Days 2026
Disruptive Pharma will attend Nordic Life Science Days in Stockholm, where Peter Åsberg and Martina Ferneman will meet with potential partners from the pharmaceutical and biotechnology industries. During the conference, we look forward to discussing Formulite®, oral drug development and formulation challenges where our technology can create...
21 August, 2026
A milestone worth celebrating at Nasdaq Stockholm
Friday marked a special moment for Disruptive Pharma, as colleagues, Board members and guests gathered at Nasdaq Stockholm to celebrate the company's new chapter as a listed company. The opening bell ceremony was an opportunity to reflect on how far Disruptive Pharma and Formulite® have come – from many years of scientific research and...
During summer 2026, Disruptive Pharma welcomed Johannes Schwarz, a Master's student at Uppsala University, to our labs in Uppsala through the SweDeliver Summer Internship programme. During his internship, Johannes explored how different formulations influence the tableting process and the properties of the final tablets. The project provided...
11 June, 2026
CEO update: Disruptive Pharma and Formulite®
In this Swedish-language presentation, CEO Peter Åsberg gives an update on Disruptive Pharma, the company’s proprietary Formulite® technology platform, and the next phase of development. Watch the presentation on YouTube: https://www.youtube.com/watch?v=IWPt4QuAQG8&t=87s
